Erectile Function Following 125I Permanent Prostate Brachytherapy: 5- and 8-Year Results in 1411 Men
Amy Hayden(BC Cancer Agency), William Morris(Vanderbilt University), David Petrik(BC Cancer Agency), Tom Pickles, Vincent Lapointe, Michael McKenzie(Provincial Health Services Authority), Mira Keyes(BC Cancer Agency), Ingrid Spadinger
Cited by 1
Related Papers
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319
Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
|Journal of Clinical Oncology|2015|261
Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients
|International Journal of Radiation Oncology*Biology*Physics|2008|180